Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04763980

Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer

This clinical trial studies barriers to genetic testing in African American men with prostate cancer and whether tailored, culturally relevant genetic testing education provided by a community-based health coach is beneficial in improving knowledge, attitudes, and awareness of genetic testing. Information gained from this study, may help researchers better understand and learn more about how to increase access to germline genetic testing in underrepresented populations.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

San Francisco Veterans Administration Medical Center, San Francisco, California, United States

Loading trial locations.

About this study

PRIMARY OBJECTIVES:

I. To assess uptake of genetic testing using tailored education strategies and culturally relevant cancer resources delivered by a community-based health coach (Initial Pilot Cohorts).

II. To assess barriers to the intervention (Part 1). III. To evaluate consent rate of germline testing among participants receiving the intervention (Part 2).

SECONDARY OBJECTIVES:

I. To assess decisional conflict among African American men receiving tailored education strategies and culturally relevant cancer resources on genetic testing delivered by a community-based health coach (Initial Pilot Cohorts).

II. To assess facilitators to the intervention (Part 1).

III. To assess acceptability of the intervention (Parts 1 and 2).

IV. To characterize patient and health coach use of ProGene (Part 1).

V. To evaluate completion rate of germline testing among participants receiving the intervention (Part 2).

VI. To evaluate change in participant knowledge about germline testing among patient participants (Part 2).

VII. To evaluate change in participant attitudes toward germline testing among patient participants (Part 2).

VIII. To evaluate change in decisional conflict about germline testing among patient participants (Part 2).

IX. To evaluate reach of the intervention (Part 2).

X. To evaluate barriers and facilitators to the intervention (Part 2).

XI. To identify reasons for declining germline testing.

TERTIARY OBJECTIVE:

I. To assess the germline mutation rate among African American men with prostate cancer (Initial Pilot Cohorts)

OUTLINE: The initial pilot phase of the study has concluded. Participants are assigned to Parts 1 or 2 of current study.

CLOSED TO ENROLLMENT: INITIAL PILOT COHORT A:

Participants complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may also undergo genetic testing.

CLOSED TO ENROLLMENT: INITIAL PILOT COHORT B:

Participants engage in an educational session with health coach over 60 minutes. Participants also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may undergo genetic testing.

PART 1:

Participants engage in an educational session with health coach over 60 minutes. Participants also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may undergo genetic testing.

PART 2:

Participants in this secondary pilot engage in an educational session with health coach over 60 minutes. Participants also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may undergo genetic testing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CLOSED TO ENROLLMENT: INITIAL PILOT COHORT:

Participants:

  • Age >=18 years old.
  • Able to speak and read in English.
  • Have no known cancer risk genetic mutation.
  • Self-identify as Black or African American.
  • Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per National Comprehensive Cancer Network (NCCN) guidelines.

ENROLLING: PART 1:

Participants:

  • Age >=18 years old.
  • Able to speak and read in English.
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Able to verbally consent.
  • Self-identifies as Black or African-American.
  • Self-reports a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer.

Note: Participants may or may not have had germline testing in the past, as a range of experiences is valuable for holistic feedback.

Providers:

  • Self-identifies as a medical oncologist or genetics provider.
  • Able to speak and read in English.
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Able to verbally consent.

ENROLLING: PART 2:

Participants:

  • Age >=18 years old.
  • Able to speak and read in English.
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Able to provide written informed consent.
  • Have no known cancer risk genetic mutation.
  • Self-identify as Black or African American.
  • Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per NCCN guidelines.
  • For patients recruited from the clinic: Presence of an oncology appointment within 3 months where germline testing will be discussed.

Exclusion criteria

CLOSED TO ENROLLMENT: INITIAL PILOT COHORT.

  • Prior germline genetic test.
  • Age <18 years old.
  • Unable to read or answer forms.

ENROLLING: PART 1:

  • Contraindication to any study-related procedure or assessment.

ENROLLING: PART 2:

  • Self-reports prior germline genetic test.
  • Contraindication to any study-related procedure or assessment.

Treatment and study plan

Educational Intervention

Other

Participate in educational session with health coach

Other names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

Genetic Testing

Other

Undergo genetic testing

Other names: Genetic analysis, Genetic Examination, Genetic Test

Survey Administration

Other

Complete surveys throughout course of study.

Other names: Questionnaire Administration

ProGene Artificial Intelligence (AI) Platform

Other

AI Platform to be used by health coach during sessions

Other names: ProGene AI Platform, ProGene

Interviews

Other

Participant and provider interviews will be conducted by study staff.

Other names: Participant interviews

Primary outcomes

  1. Consent rate for germline testing (Initial Pilot Cohort and Part 2)

    Time frame: At baseline (1 day)

    The consent rate for each cohort will be defined as proportion of patients enrolled in the study who agree to undergo germline genetic testing with Color genomics. The point estimate and 90% confidence interval will be provided.

  2. Frequency of reported barriers to interventions (Part 1)

    Time frame: Up to 30 days

    Participant- and provider-reported barriers to engaging in the intervention for participants to make an informed decision about germline testing will be reported descriptively.

Secondary outcomes

  1. Decisional conflict scale score (Initial Pilot Cohort and Part 2)

    Time frame: Up to 120 days

    The decisional conflict scale will be scored using a validated instrument. Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict). Summary statistics with median and interquartile range will be obtained.

  2. Frequency of reported facilitators to interventions (Part 1 and 2)

    Time frame: Up to 120 days

    Participant- and provider-reported facilitators to engaging in the intervention for participants to make an informed decision about germline testing.

  3. Mean score of theoretical framework of acceptability (TFA) questionnaire (Part 1 and Part 2)

    Time frame: Up to 120 days

    Participant-reported acceptability of the intervention will be described using the TFA questionnaire. Scores on the TFA items will be averaged across all participants. Items will be scored on a 5-point scale: 1= Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5= Completely agree. All negatively worded items will be reverse-scored for a total score of 24-120. Higher scores represent greater acceptability (more positive attitudes). The mean score and standard deviation will be reported.

  4. Number of recorded inputs into ProGene (Part 1)

    Time frame: Up to 30 days

    The number of recorded data inputs into the ProGene platform will be reported descriptively to characterize patient-participant and health coach use of ProGene.

  5. Proportion of patient participants who complete germline testing (Part 2)

    Time frame: Up to 120 days

    The completion rate is defined as the proportion of patient-participants who complete germline testing within 90 days of intervention will be reported.

  6. Mean score of adapted KnowGene germline testing knowledge survey (Part 2)

    Time frame: Up to 120 days

    Knowledge of tumor genetic testing adapted from a validated survey from Blanchette, et al.+ select questions from a survey from Rogith, et al. will be utilized to measure the level of cancer genomic testing knowledge. "Don't know" will be scored as incorrect. The proportion of correct responses will be calculated to generate a total score between 0-100, with a higher score indicating greater knowledge. No items will be weighted. Since all items are required, we anticipate missing responses will be rare. Any missing data will be managed case-by-case post-hoc.

  7. Mean score of genetic testing attitudes survey (Part 2)

    Time frame: Up to 120 days

    Attitude and expectations measure for tumor genetic testing is a 17-item measure adapted from a validated survey from Blanchette, et al. including one open-ended investigator-created item. Items on the attitude scoring scale range from "Yes" = 1 and "No" or "Unsure" = 0

  8. Proportion of individuals classified as "supporters" (Part 2)

    Time frame: Up to 120 days

    Proportion of individuals classified as "supporters" of genetic testing

  9. Proportion of participants who consent to study (Part 2)

    Time frame: Up to 120 days

    Proportion of participants who consent to study among those approached as potential participants will be reported

  10. Frequency of reported barriers to interventions (Part 2)

    Time frame: Up to 120 days

    Participant- and provider-reported barriers to engaging in the intervention for participants to make an informed decision about germline testing will be reported descriptively.

  11. Frequency of reasons for declining testing (Part 2)

    Time frame: Up to 120 days

    Patient-participant reported reasons for declining germline testing will be reported descriptively.

Other outcomes

  1. Highly penetrant germline genetic mutation rate and variants of unknown significance among all participants who undergo germline testing

    Time frame: At baseline and exit/follow-up visit (up to 2 days)

    Will be determined by the sum of all alterations detected on Color genomics. Summary statistics will be obtained.

Study contacts

Contact information is provided by the study sponsor or research team.

UCSF Genitourinary Medical Oncology Recruitment

CONTACT

[email protected]

877-827-3222

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Lazarex Cancer Foundation

Registry information

Official study title

Navigate Study: Use of a Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African American Men With Prostate Cancer

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Feb 21, 2021
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.